Dravet syndrome (DS), a rare form of epilepsy, occurs in approximately 1 in 20,000 live births and is associated with a significant humanistic and economic burden on caregivers, families, and patients. While many medications are used in treating the seizures associated with DS, there are currently no FDA-approved treatments, and nearly all patients continue to have uncontrolled seizures and other medical needs throughout their lifetime. Several investigational therapies are in late-stage development with the potential to provide new treatment options to address the serious medical needs for patients with DS.
From Alzheimer's to Epilepsy and Multiple Sclerosis Elsevier's Office of Continuing Medical Education offers complimentary CME courses for a variety of neurology activities.
The 71st American Epilepsy Society (AES) Annual Meeting was held in Washington, DC, December 1-5, 2017. The conference attracts clinicians, scientists investigating basic and clinical aspects of epilepsy, and other professionals interested in seizure disorders. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on seizure disorders.
MSPARIS2017: Clinical Updates on Disease Modifying Therapies to Improve Outcomes for Patients with Multiple SclerosisFormat: Medical Meeting Reporter
This educational activity will feature content presented at the MS Paris 2017 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France. Four expert faculty will examine recent prognosis and diagnostic strategies of multiple sclerosis. An analysis of clinical trial data of current and emerging disease modifying therapies as presented at the Joint ACTRIMS-ECTRIMS meeting will be discussed. The faculty will also review how to implement recent scientific data to safely manage patients with multiple sclerosis for optimal outcomes. Upon completion of this activity, learners will gain a better understanding of recent clinical trial data for the treatment of multiple sclerosis, ultimately improving patient outcomes.
This symposium will bring together experts from around the world to engage in a lively in-depth discussion on the key clinical questions and controversies in the diagnosis of lysosomal storage diseases (LSDs) and the future direction of LSD management. This program will address the consequences of delayed diagnosis and treatment initiation, and help you better understand diagnostic options. The experts will discuss genotype–phenotype correlations and their significance for daily clinical practice, and provide perspectives on emerging therapeutic developments and strategies for the treatment of LSDs.
This CME program will feature content presented at the the 69th Annual American Academy of Neurology (AAN) Meeting held in Boston, Massachusetts. Three expert faculty will analyze recent therapeutic advances in the treatment and management of patients with multiple sclerosis. The clinical relevance of emerging and emerged trial data will be reviewed. Faculty will discuss strategies for utilizing the multidisciplinary team approach to develop and implement personalized treatment plans, accommodating patient-specific disease characteristics. Upon completion of the activity, learners will have a better grasp of evolving science in the field of multiple sclerosis as it relates to clinical practice.
The 59th Annual Scientific Meeting of the American Headache Society (AHS) was held in Boston, Massachusetts, June 8 to June 11, 2017. The conference attracts medical professionals involved in the care of patients with head, neck, and orofacial pain. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on migraine.
AAIC 2017: AN UPDATE ON SCIENTIFIC ADVANCES AND CLINICAL STRATEGIES IN ALZHEIMER’S DISEASE FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE®Format: Conference Reporter
The Alzheimer’s Association International Conference® 2017 (AAIC®) was held in London, England, July 16-20, 2017. As the largest international meeting dedicated to advancing dementia science, AAIC unites leaders from more than 70 countries to discuss the latest dementia study results and theories. In this activity, 2 experts summarize the key learnings from this year’s conference.
AN UPDATE ON SCIENTIFIC ADVANCES AND CLINICAL STRATEGIES IN MIGRAINE AND OTHER PRIMARY HEADACHE DISORDERSFormat: Conference Reporter
The 18th Congress of the International Headache Society (IHC) was held in Vancouver, BC, Canada, September 7 to 10, 2017. The conference attracts medical professionals involved in the care of patients with new developments in the advancement of headache science, education, and management. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on migraine.
Migraine treatment includes both preventive therapy, aimed at reducing attack frequency and severity, and acute therapy, for aborting attacks. For acute therapy, the most widely used drugs are NSAIDs and triptans. Routes of triptan administration include oral, intranasal, suppository, subcutaneous, and transdermal iontophoretic, as well as a variety of device-enhanced delivery options. Relatively slow onset of action remains a limitation for these formulations, except for the injectable delivery. Novel routes of delivery, such as intradermal, are in development, holding the promise of rapid absorption into the systemic circulation and, thus, rapid relief. Ultimately, the abundance of delivery options provides more choices to patients with migraine.
AN UPDATE ON EMERGING S1P THERAPEUTICS FOR THE MANAGEMENT OF PATIENTS WITH RELAPSING MULTIPLE SCLEROSISFormat: Conference Reporter
This CME program will highlight data presented at the 7th Annual Joint ECTRIMS – ACTRIMS Meeting in Paris, France. The three expert faculty will analyze recent therapeutic advances in the treatment and management of multiple sclerosis (MS). The clinical relevance of emerging and emerged trial data, particularly regarding S1P therapeutics, will be assessed. Faculty will outline strategies for utilizing the multidisciplinary team approach to develop and implement data-driven, tailored treatment plans in clinical practice. Upon completion of this CME activity, learners will have a better grasp of evolving science in the field of MS in order to improve outcomes and quality of care.
An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease: Conference Reporter from AD/PD™ 2017Format: Conference Reporter
The Alzheimer’s & Parkinson’s Diseases (AD/PD™) 13th International Conference was held in Vienna, Austria, March 29 to April 2, 2017. The conference attracts international medical and scientific professionals worldwide and is at the forefront of unraveling the mechanisms and improving the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD). In this activity, 2 experts summarize the key learnings from this year’s conference focusing on AD.
This symposium archive will provide participants with the opportunity to assess remaining challenges in the care of patients with spasticity. In addition to reviewing appropriate use of chemodenervation and other treatments, this activity will also highlight techniques for improved communication between physicians and patients regarding the causes of functional impairments, individualized treatment options, customized goals of treatment, and the need for post-intervention rehabilitation and home programs via interactive video case presentations.
The content for this activity is based on the satellite symposium, Spasticity Video Challenge: A Look at Methods for Addressing Difficult Cases, that was presented at the AAPM&R Annual Assembly in New Orleans, Louisiana on October 22, 2016.
This CME activity will focus on the management of patients with familial hypercholesterolemia and the role of PCSK9 inhibitors in this therapeutic area. Expert faculty will review the science of PCSK9, the updated standards of care for the diagnosis, and FH scoring and management of patients with familial hypercholesterolemia. Clinical trial data of PCSK9 inhibitors for the treatment of familial hypercholesterolemia, including long-term efficacy and safety data, will be analyzed. The faculty will guide physicians on how to implement a multidisciplinary approach to optimally manage patient-specific disease to improve outcomes for patients with familial hypercholesterolemia. Upon completing this activity, physicians will gain knowledge on the most up-to-date care for this cohort of patients.